These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28318251)

  • 1. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
    Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
    J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
    Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Wu X; Wang Y; Wan S; Zhang J
    J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
    Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
    Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.
    Ou SH; Tan J; Yen Y; Soo RA
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):447-56. PubMed ID: 22500682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
    Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
    Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
    Liu S; Yang H; Jiang Y; Zhang T; Yan R; Zhang J
    Future Med Chem; 2018 Jul; 10(14):1705-1720. PubMed ID: 29961337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
    Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
    Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS1 Kinase Inhibitors for Molecular-Targeted Therapies.
    Al-Sanea MM; Abdelazem AZ; Park BS; Yoo KH; Sim T; Kwon YJ; Lee SH
    Curr Med Chem; 2016; 23(2):142-60. PubMed ID: 26438251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
    Chin LP; Soo RA; Soong R; Ou SH
    J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer.
    Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A
    J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
    Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.